---
schema_version: "secwatch.filing_event.v1"
accession: "0001104659-26-062865"
form_type: "8-K"
ticker: "OTLK"
cik: "0001649989"
company_name: "Outlook Therapeutics, Inc."
filed_at: "2026-05-15T23:55:16+00:00"
generated_at: "2026-05-18T10:06:42.229448+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.7
calibrated_materiality_score: 0.7
confidence: "high"
source: SEC EDGAR
---

# Outlook Therapeutics Q2 FY2026 net loss narrows to $4.5M; FDA decision on ONS-5010 expected May 2026

## Summary
- Net loss of $4.5M ($0.05/sh) vs $46.4M ($1.50/sh) YoY; adjusted net loss $14.1M ($0.16/sh).
- LYTENAVA unit sales in Europe down ~10% QoQ; cost reduction steps initiated to improve margins.
- Cash $7.7M as of Mar 31; raised ~$4M in March offering and $4.2M net in April registered direct offering.
- FDA formal dispute resolution meeting completed in April; written decision expected within May 2026.
- Entered Swiss distribution agreement with Mediconsult AG; targeting 2027 launch pending marketing authorization.

## SEC filing metadata
- accession: 0001104659-26-062865
- form_type: 8-K
- ticker: OTLK
- cik: 0001649989
- company_name: Outlook Therapeutics, Inc.
- filed_at: 2026-05-15T23:55:16+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.7
- calibrated_materiality_score: 0.7
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1649989/000110465926062865/0001104659-26-062865-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1649989/000110465926062865/tm2614868d1_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001104659-26-062865
- JSON: https://secwatch.observer/filing/0001104659-26-062865.json
- Plain text: https://secwatch.observer/filing/0001104659-26-062865.txt

## Key facts
- Earnings Releases
  Outlook Therapeutics, Inc. reported second fiscal quarter ended March 31, 2026 results: net income net loss attributable to common stockholders of $4.5 million, or $0.05 per basic and diluted share.
  - Period: second fiscal quarter ended March 31, 2026
  - Net income: net loss attributable to common stockholders of $4.5 million, or $0.05 per basic and diluted share
  - Result: reported results
  source text: Outlook Therapeutics reported net loss attributable to common stockholders of $4.5 million, or $0.05 per basic and diluted share.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1649989/000110465926062865/0001104659-26-062865-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.